AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) on Tuesday posted second-quarter results that delivered a substantial non-GAAP earnings beat, while revenue landed close enough to expectations to be considered inline. The biopharmaceutical company, which focuses on technically challenging generic and proprietary injectable, inhalation, and intranasal products, reported non-GAAP EPS of $0.91 for the three months ended June 30, 2026, against the $0.63 consensus analyst estimate. Revenue came in at $183.9 million, compared with the $185.7 million analysts had modeled, a shortfall of less than 1%.
A profit-led quarter
The standout in the report was earnings. Non-GAAP EPS exceeded the analyst target by roughly 44%, a gap that points to stronger-than-expected profitability or a favorable mix within the product portfolio. Revenue was effectively flat versus consensus, and at less than 1% below the estimate, it falls into the inline category rather than a miss.
Amphastar sells more than 25 products used largely in hospital and urgent care settings, including BAQSIMI (glucagon) nasal powder, Primatene MIST, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone, and Cortrosyn, along with insulin API products for the injectable insulin market. The company is headquartered in Rancho Cucamonga, California.
How the market is reacting
Shares moved up roughly 2.7% in after-hours trading, a signal that investors are focusing on the earnings outperformance rather than the marginal revenue shortfall. The gain follows a mixed stretch in the weeks leading up to the print:
- Past week: down approximately 2.8%
- Past two weeks: up approximately 5.0%
- Past month: up approximately 4.2%
The positive after-market move suggests the second-quarter profit surprise is building on the stock's recent momentum.
Quarterly scorecard
- Reported revenue: $183.9 million vs. $185.7 million estimated (inline)
- Reported non-GAAP EPS: $0.91 vs. $0.63 estimated (beat)
- After-market share movement: +2.7%
No guidance, steady estimates
Amphastar did not issue formal outlook guidance in the release, so the market reaction appears to be driven by the reported figures rather than any forward-looking statement. Current analyst projections put third-quarter revenue near $203.3 million with non-GAAP EPS of about $0.83. For the full year, the sell-side is modeling revenue of approximately $759.8 million and non-GAAP EPS of roughly $2.63.
Investors seeking more historical context on the company's quarterly performance can review the earnings history here. To see where analysts expect the numbers to move from here, view the latest estimates and projections.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Always conduct your own research and consider your risk tolerance before making investment decisions.
Read full article here »
View the Zacks #1 Rank List
Amphastar Pharmaceuticals (NASDAQ:AMPH) Beats Q2 Earnings Estimates, Shares Rise After Hours
AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) on Tuesday posted second-quarter results that delivered a substantial non-GAAP earnings beat, while revenue landed close enough to expectations to be considered inline. The biopharmaceutical company, which focuses on technically challenging generic and proprietary injectable, inhalation, and intranasal products, reported non-GAAP EPS of $0.91 for the three months ended June 30, 2026, against the $0.63 consensus analyst estimate. Revenue came in at $183.9 million, compared with the $185.7 million analysts had modeled, a shortfall of less than 1%.
A profit-led quarter
The standout in the report was earnings. Non-GAAP EPS exceeded the analyst target by roughly 44%, a gap that points to stronger-than-expected profitability or a favorable mix within the product portfolio. Revenue was effectively flat versus consensus, and at less than 1% below the estimate, it falls into the inline category rather than a miss.
Amphastar sells more than 25 products used largely in hospital and urgent care settings, including BAQSIMI (glucagon) nasal powder, Primatene MIST, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone, and Cortrosyn, along with insulin API products for the injectable insulin market. The company is headquartered in Rancho Cucamonga, California.
How the market is reacting
Shares moved up roughly 2.7% in after-hours trading, a signal that investors are focusing on the earnings outperformance rather than the marginal revenue shortfall. The gain follows a mixed stretch in the weeks leading up to the print:
The positive after-market move suggests the second-quarter profit surprise is building on the stock's recent momentum.
Quarterly scorecard
No guidance, steady estimates
Amphastar did not issue formal outlook guidance in the release, so the market reaction appears to be driven by the reported figures rather than any forward-looking statement. Current analyst projections put third-quarter revenue near $203.3 million with non-GAAP EPS of about $0.83. For the full year, the sell-side is modeling revenue of approximately $759.8 million and non-GAAP EPS of roughly $2.63.
Investors seeking more historical context on the company's quarterly performance can review the earnings history here. To see where analysts expect the numbers to move from here, view the latest estimates and projections.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Always conduct your own research and consider your risk tolerance before making investment decisions.
Read full article here »